期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

大肠癌的分子靶向治疗进展 被引量：5

Advancement in molecular targeted therapy of colorectal cancer
下载PDF
导出
摘要 对于无法手术或手术后复发、转移的结肠癌,主要依靠氟尿嘧啶类、铂类和伊立替康等药物为主的化疗,但易产生耐药性。近年国际上出现的分子靶向治疗,为大肠癌的治疗开辟了一条新途径。抗血管内皮生长因子单抗和抗表皮生长因子受体单抗等分子靶向药物联合化疗,可以明显提高化疗效果,且耐受性较好。分子靶向治疗正在成为除手术、化疗和放疗以外治疗大肠癌的第4种方法。 For patients with unresectable or recurrent/metastatic colon cancer,chemotherapy with fiuoropyrimidines,cisplatin/oxaliplatin and irinotecan is the main treatment,but multi-drug resistance occurs very often.The molecular targeted therapy of colorectal cancer has developed rapidly all over world in recent years.Results of some multi-nation,multi-center,randomized clinical trials show that targeted medicine combined with chemotherapy is effective and the side effects are well-tolerable.So it has been the 4th alternative method in treating colorectal cancer excepting surgery,chemotherapy and radiotherapy.
作者 张伟华 郝丽萍
机构地区 甘肃省肿瘤医院消化科 珠海市第二人民医院消化科
出处 《兰州大学学报（医学版）》 CAS 2011年第2期69-73,78,共6页 Journal of Lanzhou University（Medical Sciences）
关键词 大肠癌 分子靶向治疗 贝伐单抗 西妥昔单抗 帕尼单抗 colorectal cancer molecular targeted therapy bevacizumab cetuximab panitumumab
分类号 R730.58 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1HURWITZ H, FEHRENBACHER L, NOVOTNY W, et al. Bevacizumab plus irinotecan, fluorouracil, and leu- covorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335-2342.
  • 2CHARLES S, JOHN M, JOSE B. Randomized, con- trolled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study[J]. J Clin Oncol, 2008, 26(4): 689-690.
  • 3VAN E, RIVERA F, BERRY S, et al. Safety and efficacy of first-line bevacizumab with FOL- FOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study[J]. Ann Oncol, 2009, 20(11): 1842-1847.
  • 4WELCH S, KRZYZANOWSKA M, Moore M J, et al. Phase H study of capecitabine, irinotecan, and be- vacizumab (XELIRI-A) in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27(Suppl 15): 15 019.
  • 5WHYTE S, PANDOR A, STEVENSON M, et al. Be- vacizumab in combination with fiuoropyrimidine- based chemotherapy for the first-line treatment of metastatic colorectal cancer[J]. Health Technol As- sess, 2010, 14(2): 47-53.
  • 6KOZLOFF M, gators of the sociated with YOOD M, BERLIN J, et al. Investi- BRiTE study, clinical outcomes as- bevacizumab-containing treatment ofmetastatic colorectal cancer: the BRiTE observa- tional cohort study[J]. Oncologist, 2009, 14(9): 862- 870.
  • 7ALLEGRA C, YOTHERS G, CONNELL M, et al. Ini- tial safety report of NSABP C-08: a randomized phase m study of modified FOLFOX6 with or with- out bevacizumab for the adjuvant treatment of pa- tients with stage Ⅱ or Ⅲ colon cancer[J]. J Clin On- col, 2009, 27(20): 3385-3 390.
  • 8SALTZ L B, MEROPOL N J, LOEHRER P J, et al. Phase ]I trial of cetuximab in patients with refrac-tory colorectal cancer that expresses the epidermal growth factor receptor[J]. J Clin Oncol, 2004, 22(7): 1 201-1 208.
  • 9VENOOK A, NIEDZWIECKI D, HOLLIS D, et al. Phase Ⅲ study of irinotecan/5FU/LV (FOLFIRI)or oxaliplatin/5FU/LV (FOLFOX)-+-cetuximab for pa- tients with untreated metastatic adenocarcinoma ofthe colon or rectum (MCRC): CALGB 80203 pre- liminary results[J]. Journal of Clinical Oncology, 2006, 24(Suppl 18): 3 509.
  • 10RAOUL J L, Van LAETHEM J L, PEETERS M, et al. Cetuximab in combination with irinotecan/5- fluorouracil/folinic acid (FOLFIRI) in the initialtreatment of metastatic colorectal cancer: a multi-centre two-part phase I / II study[J]. BMC Cancer, 2009, 14(9): 112.

同被引文献42

  • 1黄红艳,江泽飞,王涛,张少华,边莉,曹阳,吴世凯,宋三泰.贝伐珠单抗联合多西他赛治疗Her-2阴性复发转移性乳腺癌的疗效观察[J].中国癌症杂志,2011,21(3):220-224. 被引量：17
  • 2邓薇,沈琳.胃癌靶向药物治疗进展[J].中国医学前沿杂志（电子版）,2013,5(1):29-41. 被引量：8
  • 3Bijnsdorp IV, Kruyt FA, Fukushima M, et al. Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growthfactor receptor inhibitor erlotinib in human colorectal cancer cell lines[ J]. Cancer Sci, 2010,101 (2) :440 - 447.
  • 4Tabemero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration [ J ] ? Oncologist, 2008,13(2) :113 - 119.
  • 5De Reyni~s A, Boige V, Milano G, et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response sig- nature [ J ]. J Clin Oncol, 2008,26 ( 13 ) :2228 - 2230.
  • 6Tabernero J, Van Cutsem E, Dlaz - Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leueovorin, and oxaliplatin in the first - line treatment of metastatic eolorectal cancer [ J ]. J Clin Oneol, 2007,25 ( 33 ) :5225 - 5232.
  • 7Oberg A L, French A J, Sarver A L, et al. miRNA expres- sion in colon polyps provides evidence for a multihit model of colon cancer [J]. PLoS One, 2011; 6(6): e20465.
  • 8Toshinori H, Daniel J Weisenberger, Christopher P E. Genome-scale analysis of aberrant DNA methylation in colorectal cancer [J]. Genome Res, 2012, 22(2): 271-282.
  • 9Lin S Y, Yeh K T, Chen W T. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its rela- tionship to clinical features [J]. Oncol Rep, 2004, 11(2): 341-348.
  • 10Ambady S, Wu Z Y. Identification of novel microRNAs in xenopus laevis metaphase I1 arrested eggs [J]. Genesis, 2012, 50(3): 286-299.

引证文献5

二级引证文献15

兰州大学学报（医学版）
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部